The efficacy of *** adjuvant chemotherapy on biliary tract cancer after R0 resection

作     者：Young Saing Kim Chi-Young Jeong Haa-Na Song Tae Hyo Kim Hong Jun Kim Young-Joon Lee Soon Chan Hong 

作者机构：Division of Hematology and Oncology Department of Internal MedicineGachon University Gil Medical Center Incheon 405.706 South Korea Department of Surgery Institute of Health Sciences Gyeongsang National University Hospital Gyeongsang National University School of Medicine 79 Gangnam-roJinju 660.702 South Korea Department of Internal Medicine Institute of Health Sciences Gyeongsang National University Hospital Gyeongsang National University School of Medicine Jinju 660.702 South Korea. 

出 版 物：《Chinese Journal of Cancer》 (Chinese Journal of Cancer)

年 卷 期：2017年第36卷第5期

页      面：222-230页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Biliary tract cancer Adjuvant chemotherapy Fluoropyrimidine R0 resection Prognosis 

摘      要：Background: The optimal treatment strategy for biliary tract cancer(BTC) after curative?intent resection remains con?troversial. The purpose of this study was to evaluate the efficacy of fluoropyrimidine?based adjuvant chemotherapy for BTC patients undergoing microscopically margin?negative(R0) ***: We retrospectively analyzed the clinical data of BTC patients who underwent curative?intent R0 resection. Patients were eligible if they received either fluoropyrimidine?based adjuvant chemotherapy or observation after R0 ***: A total of 153 patients were included. In the entire patient cohort, no significant differences were observed in 5?year overall survival(OS) rates(48.4% vs. 39.6%, P = 0.439) or 3?year recurrence?free survival(RFS) rates(49.1% vs. 39.5%, P = 0.299) between patients who received fluoropyrimidine?based adjuvant chemotherapy or observation. However, for patients with stages Ⅱ and Ⅲ BTC, chemotherapy significantly improved 5?year OS rate(52.4% vs. 35.6%, P = 0.002) and 3?year RFS rate(55.5% vs. 39.1%, P = 0.021) compared with ***: Fluoropyrimidine?based adjuvant chemotherapy may prolong the survival of patients with stages Ⅱ and Ⅲ BTC after R0 resection.